PBM CIK: 1985062

Psyence Biomedical Ltd.

  • Canada
  • Healthcare
  • Biotech
Metrics score locked — part of Premium

Price analysis

Chart shows the share price.

Data table: Stock Price (EUR)
Point in timePrice
Oct 27, 2023249,250.8 EUR
Nov 3, 2023245,499 EUR
Nov 10, 2023245,937.8 EUR
Nov 17, 2023245,756.4 EUR
Nov 24, 2023252,282.6 EUR
Dec 1, 2023241,379.3 EUR
Dec 8, 2023239,224.2 EUR
Dec 15, 2023232,320.5 EUR
Dec 22, 2023206,244 EUR
Dec 29, 2023195,984.7 EUR
Jan 5, 2024225,126.1 EUR
Jan 12, 2024239,901.4 EUR
Jan 19, 2024143,161.5 EUR
Jan 26, 202450,665.3 EUR
Feb 2, 202431,226.9 EUR
Feb 9, 202417,667.3 EUR
Feb 16, 202414,561.4 EUR
Feb 23, 202411,768.5 EUR
Mar 1, 202412,398.2 EUR
Mar 8, 202445,237.2 EUR
Mar 15, 202427,758.5 EUR
Mar 22, 202423,820.8 EUR
Mar 29, 202424,714.3 EUR
Apr 5, 202421,294.9 EUR
Apr 12, 202417,778.3 EUR
Apr 19, 202414,938.5 EUR
Apr 26, 202418,791.2 EUR
May 3, 202425,304.8 EUR
May 10, 202421,743.7 EUR
May 17, 202418,803.6 EUR
May 24, 202417,924.1 EUR
May 31, 202416,198.1 EUR
Jun 7, 202414,409.2 EUR
Jun 14, 202413,247.4 EUR
Jun 21, 20248,552.2 EUR
Jun 28, 20246,568.2 EUR
Jul 5, 20246,301.1 EUR
Jul 12, 20246,693.3 EUR
Jul 19, 20248,867 EUR
Jul 26, 202412,538.8 EUR
Aug 2, 202411,897.1 EUR
Aug 9, 202411,357 EUR
Aug 16, 202411,448 EUR
Aug 23, 202410,642.9 EUR
Aug 30, 20248,667.3 EUR
Sep 6, 20244,031.9 EUR
Sep 13, 20243,299.6 EUR
Sep 20, 20242,518.8 EUR
Sep 27, 20242,268.6 EUR
Oct 4, 20242,125.1 EUR
Oct 11, 20242,078.5 EUR
Oct 18, 20242,333.6 EUR
Oct 25, 20242,100.2 EUR
Nov 1, 20241,485.7 EUR
Nov 8, 20241,653.6 EUR
Nov 15, 20241,129.5 EUR
Nov 22, 2024990.4 EUR
Nov 29, 20241,023.7 EUR
Dec 6, 2024700 EUR
Dec 13, 2024549.7 EUR
Dec 20, 2024956.4 EUR
Dec 27, 2024676.8 EUR
Jan 3, 2025612.9 EUR
Jan 10, 2025515.6 EUR
Jan 17, 2025543.2 EUR
Jan 24, 2025543.1 EUR
Jan 31, 2025472.1 EUR
Feb 7, 2025411.1 EUR
Feb 14, 2025416.1 EUR
Feb 21, 2025388.2 EUR
Feb 28, 2025372.2 EUR
Mar 7, 2025264.8 EUR
Mar 14, 2025225 EUR
Mar 21, 2025180.4 EUR
Mar 28, 2025181.8 EUR
Apr 4, 2025130.6 EUR
Apr 11, 2025123.7 EUR
Apr 18, 2025120.5 EUR
Apr 25, 2025151.3 EUR
May 2, 2025119.6 EUR
May 9, 2025130.9 EUR
May 16, 2025181.5 EUR
May 23, 2025151.7 EUR
May 30, 2025169.1 EUR
Jun 6, 2025189 EUR
Jun 13, 2025154.1 EUR
Jun 20, 2025161.5 EUR
Jun 27, 2025163.9 EUR
Jul 4, 2025172.8 EUR
Jul 11, 2025171.7 EUR
Jul 18, 2025169.7 EUR
Jul 25, 2025383.2 EUR
Aug 1, 202580.8 EUR
Aug 8, 2025134.5 EUR
Aug 15, 2025109.3 EUR
Aug 22, 2025109 EUR
Aug 29, 202594.2 EUR
Sep 5, 202589.8 EUR
Sep 12, 2025121.3 EUR
Sep 19, 2025158.4 EUR
Sep 26, 2025104.1 EUR
Oct 3, 2025107.2 EUR
Oct 10, 2025121.9 EUR
Oct 17, 2025117.7 EUR
Oct 24, 2025112.4 EUR
Oct 31, 2025106.8 EUR
Nov 7, 202578.1 EUR
Nov 14, 202590.9 EUR
Nov 21, 202550.5 EUR
Nov 28, 202551.8 EUR
Dec 5, 202559 EUR
Dec 12, 202552.6 EUR
Dec 19, 202533.4 EUR
Dec 26, 202530.8 EUR
Jan 2, 202626.6 EUR
Jan 9, 202626.8 EUR
Jan 16, 202622.5 EUR
Jan 23, 20263.9 EUR
Jan 30, 20263.4 EUR
Feb 6, 20262.7 EUR
Feb 13, 20262.6 EUR
Feb 20, 20262.1 EUR
Feb 27, 20262.2 EUR
Mar 6, 20262.2 EUR
Mar 13, 20262.1 EUR
Mar 20, 20262.1 EUR
Mar 27, 20262.2 EUR
Apr 3, 20262.1 EUR
Apr 10, 20262.3 EUR
Apr 17, 20266.4 EUR
Apr 24, 20266.8 EUR
May 1, 20265.3 EUR
May 8, 20264.8 EUR
May 15, 20264.2 EUR
May 22, 20263.5 EUR
May 29, 20263.6 EUR
Jun 5, 20263 EUR
Jun 12, 20262.9 EUR
Jun 19, 20262.7 EUR
Jun 26, 20262.6 EUR
Jul 3, 20262.7 EUR
Jul 10, 20262.6 EUR
Jul 17, 20262.7 EUR
Jul 24, 20262.6 EUR
Jul 31, 20262.8 EUR
Aug 7, 20263 EUR
Aug 14, 20263 EUR
Aug 21, 20263.7 EUR
Aug 28, 20263.6 EUR
Sep 4, 20263.9 EUR
Sep 11, 20264.7 EUR
Sep 18, 20265.8 EUR
Sep 25, 20264.9 EUR
Oct 2, 20264.6 EUR
Oct 9, 20264.4 EUR
Oct 16, 20263.8 EUR
Oct 23, 20263.7 EUR
Oct 26, 20263.3 EUR

Price as of: Oct 26, 2026 closing price

Data source:Twelve Data

Key metrics overview

Metrics score locked — part of Premium
Unlock metrics and scores View Premium
Valuation
Available with Premium/ 100
  • Price-to-Earnings Ratio No meaningful value available
  • Price-to-Sales Ratio Available with Premium
  • Price-to-Free-Cashflow Available with Premium
  • Growth-Adjusted P/E Available with Premium
Growth
Available with Premium/ 100
  • Revenue Growth No meaningful value available
  • Earnings Growth Available with Premium
  • Free Cash Flow Growth Available with Premium
  • Net Margin Change Available with Premium
  • Free Cash Flow Margin Change Available with Premium
  • Earnings-per-Share Growth Available with Premium
  • Growth Consistency Available with Premium
Profita­bility
Available with Premium/ 100
  • Return on Equity −58.62%
  • Return on Assets Available with Premium
  • Return on Invested Capital Available with Premium
  • Operating Profit Margin Available with Premium
  • Net Profit Margin Available with Premium
Stability
Available with Premium/ 100
  • Revenue Stability 100 / 100
  • Earnings Stability Available with Premium
  • Cashflow Stability Available with Premium
  • Crisis Performance Available with Premium
  • Price Fluctuations Available with Premium
  • Maximum Price Loss Available with Premium
Debt
Available with Premium/ 100
  • Debt-to-Equity Ratio Available with Premium
  • Debt-to-Assets Available with Premium
  • Net Debt / EBITDA Available with Premium
  • Interest Coverage Ratio Available with Premium
Cashflow
Available with Premium/ 100
  • Operating Cashflow Available with Premium
  • Free Cashflow Available with Premium
  • Free Cashflow Margin Available with Premium
Dividends
Available with Premium/ 100
  • Dividend Yield Available with Premium
  • Dividend Payout Ratio Available with Premium
  • Dividend Growth Available with Premium
  • Years without a cut Available with Premium

Every metric explained simply

Market comparison

The Fundamentals Score is higher than that of 62% of the other companies across the entire market and 69% of the other companies in the Biotech industry.

Higher than 62% in the entire marketOpen in the Stock ScreenerHigher than 65% in HealthcareOpen in the Stock ScreenerHigher than 69% in BiotechOpen in the Stock Screener
Compare in Stock Screener

Revenue and Profit Performance

Data table: Revenue and Profit Performance (M USD)
Point in timeRevenueProfit
FY26 (Mar 31, 2026)0 M USD−6.9 M USD
FY25 (Mar 31, 2025)0 M USD1 M USD
FY24 (Mar 31, 2024)0 M USD−51.2 M USD
FY23 (Mar 31, 2023)−3.2 M USD
FY22 (Mar 31, 2022)0 M USD

All amounts in millions USD Data sources:SEC EDGARTwelve Data

More Companies

The largest other companies in Biotech, part of the Healthcare sector.

All stocks in Biotech